Abstract
Inhibition of β-amyloid (Aβ) accumulation and Aβ fibril (fAβ) formation from Aβ are attractive therapeutic targets for the treatment of Alzheimers disease (AD). While previous studies have shown anti-amyloidogenic effects of curcumin in vitro and in vivo, no studies have examined optimized turmeric extracts enriched in curcuminoids or turmerones. Three standardized turmeric extracts, HSS-838, HSS-848, and HSS-888, were prepared with different chemical profiles to investigate their potential therapeutic benefits for AD. These extracts were fingerprinted by DART TOF-MS to reveal the significant chemical complexity. In addition four curcuminoids (curcumin, tetrahydrocurcumin, demethoxycurcumin and bisdemethoxycurcumin) were also examined. We measured the effects of the extracts and curcuminoids, on the aggregation of Aβ by using a thioflavin T cell-free assay and the secretion of Aβ from human neuronal cells (SweAPP N2A cells) in vitro. All three extracts and the curcuminoids showed dose-dependent inhibition of fAβ aggregation from Aβ1-42 in the cell-free assay, with IC50 values of 5 μÊg/mL. However, only HSS-888, curcumin and demethoxycurcumin significantly decreased Aβ secretion (∼20%) in SweAPP N2A cells. Interaction matrices were used to examine possible synergistic interactions between HS-888 and the other extracts and the individual curcuminoids on Aβ aggregation. Only simple additive effects were observed for the Aβ aggregation inhibition, supporting the notion that the known curcuminoids are not strong inhibitors of this activity. However, HSS-888 showed strong inhibition of Aβ aggregation and secretion, thus indicating that there are novel bioactive molecules in this extract that might be important leads for future AD drug discovery efforts.
Keywords: Alzheimer's disease, curcuminoids, turmeric extracts, amyloid aggregation, amyloid secretion, DART TOF-MS
Current Alzheimer Research
Title: Optimized Turmeric Extracts have Potent Anti-Amyloidogenic Effects
Volume: 6 Issue: 6
Author(s): R. Douglas Shytle, Paula C. Bickford, Kavon Rezai-zadeh, L. Hou, Jin Zeng, Jun Tan, Paul R. Sanberg, Cyndy D. Sanberg, Bill Roschek Jr., Ryan C. Fink and Randall S. Alberte
Affiliation:
Keywords: Alzheimer's disease, curcuminoids, turmeric extracts, amyloid aggregation, amyloid secretion, DART TOF-MS
Abstract: Inhibition of β-amyloid (Aβ) accumulation and Aβ fibril (fAβ) formation from Aβ are attractive therapeutic targets for the treatment of Alzheimers disease (AD). While previous studies have shown anti-amyloidogenic effects of curcumin in vitro and in vivo, no studies have examined optimized turmeric extracts enriched in curcuminoids or turmerones. Three standardized turmeric extracts, HSS-838, HSS-848, and HSS-888, were prepared with different chemical profiles to investigate their potential therapeutic benefits for AD. These extracts were fingerprinted by DART TOF-MS to reveal the significant chemical complexity. In addition four curcuminoids (curcumin, tetrahydrocurcumin, demethoxycurcumin and bisdemethoxycurcumin) were also examined. We measured the effects of the extracts and curcuminoids, on the aggregation of Aβ by using a thioflavin T cell-free assay and the secretion of Aβ from human neuronal cells (SweAPP N2A cells) in vitro. All three extracts and the curcuminoids showed dose-dependent inhibition of fAβ aggregation from Aβ1-42 in the cell-free assay, with IC50 values of 5 μÊg/mL. However, only HSS-888, curcumin and demethoxycurcumin significantly decreased Aβ secretion (∼20%) in SweAPP N2A cells. Interaction matrices were used to examine possible synergistic interactions between HS-888 and the other extracts and the individual curcuminoids on Aβ aggregation. Only simple additive effects were observed for the Aβ aggregation inhibition, supporting the notion that the known curcuminoids are not strong inhibitors of this activity. However, HSS-888 showed strong inhibition of Aβ aggregation and secretion, thus indicating that there are novel bioactive molecules in this extract that might be important leads for future AD drug discovery efforts.
Export Options
About this article
Cite this article as:
Shytle Douglas R., Bickford C. Paula, Rezai-zadeh Kavon, Hou L., Zeng Jin, Tan Jun, Sanberg R. Paul, Sanberg D. Cyndy, Roschek Jr. Bill, Fink C. Ryan and Alberte S. Randall, Optimized Turmeric Extracts have Potent Anti-Amyloidogenic Effects, Current Alzheimer Research 2009; 6 (6) . https://dx.doi.org/10.2174/156720509790147115
DOI https://dx.doi.org/10.2174/156720509790147115 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Pre-Emptive Conditioning of the Ischemic Heart
Cardiovascular & Hematological Agents in Medicinal Chemistry Hypothyroidism and Cardiovascular Disease: Factors, Mechanism and Future Perspectives
Current Medicinal Chemistry Relaxin: New Functions for an Old Peptide
Current Protein & Peptide Science Editorial [Hot Topic: Recent Advances in Cancer Chemotherapy-Part I (Guest Editor: Diwan S. Rawat)]
Anti-Cancer Agents in Medicinal Chemistry Nitric Oxide Therapies in Vascular Diseases
Current Pharmaceutical Design Future Therapeutic Directions: New Medications and Insulin Delivery in a Changing World for Effective Diabetes Management
Current Drug Discovery Technologies Complications of Infective Endocarditis
Cardiovascular & Hematological Disorders-Drug Targets Anorexia of Aging
Current Nutrition & Food Science Cognitive Function and Heart Failure: The Role of the Adrenergic System
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Assessing Cardiovascular Risk in Patients with Diabetes: An Update
Current Cardiology Reviews Psychosocial Stress, Emotions and Cytokine-Related Disorders
Recent Patents on Inflammation & Allergy Drug Discovery The Triad: Erectile Dysfunction - Endothelial Dysfunction - Cardiovascular Disease
Current Pharmaceutical Design Lipid Management and Peripheral Arterial Disease
Current Drug Targets Characterization of Adipose-Derived Stem Cells: An Update
Current Stem Cell Research & Therapy Metabolic Syndrome Components in Murine Models
Endocrine, Metabolic & Immune Disorders - Drug Targets Macrophage-Assisted Inflammation and Pharmacological Regulation of the Cholinergic Anti-Inflammatory Pathway
Current Medicinal Chemistry Is Glyburide Safe in Pregnancy?
Current Pharmaceutical Biotechnology Implication for Thiazolidinediones (TZDs) as Novel Potential Anti- Inflammatory Drugs
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Healing the Diabetic Heart: Modulation of Cardiometabolic Syndrome through Peroxisome Proliferator Activated Receptors (PPARs)
Current Molecular Pharmacology Editorial (Hot Topic: Introduction to the Special Issue: Relevance of Endocrine and Metabolic Disorders in Heart Failure: From Pathophysiology to Therapeutic Approach)
Endocrine, Metabolic & Immune Disorders - Drug Targets